RT Journal Article SR Electronic T1 Outcome variables for osteoarthritis clinical trials: The OMERACT-OARSI set of responder criteria. JF The Journal of Rheumatology JO J Rheumatol FD The Journal of Rheumatology SP 1648 OP 1654 VO 30 IS 7 A1 Thao Pham A1 Désirée Van Der Heijde A1 Marissa Lassere A1 Roy D Altman A1 Jennifer J Anderson A1 Nicholas Bellamy A1 Marc Hochberg A1 Lee Simon A1 Vibeke Strand A1 Thasia Woodworth A1 Maxime Dougados A1 OMERACT-OARSI YR 2003 UL http://www.jrheum.org/content/30/7/1648.abstract AB Improvement in analysis and reporting results of osteoarthritis (OA) clinical trials has been recently obtained because of harmonization and standardization of the selection of outcome variables (OMERACT 3 and OARSI). Moreover, OARSI has recently proposed the OARSI responder criteria.This composite index permits presentation of results of symptom modifying clinical trials in OA based on individual patient responses (responder yes/no). The 2 organizations (OMERACT and OARSI) established a task force aimed at evaluating: (1) the variability of observed placebo and active treatment effects using the OARSI responder criteria; and (2) the possibility of proposing a simplified set of criteria. The conclusions of the task force were presented and discussed during the OMERACT 6 conference, where a simplified set of responder criteria (OMERACT-OARSI set of criteria) was proposed.